IDENTIFYING THE DETERMINANTS OF CLINICAL RESPONSES TO PARP INHIBITORS IN OVARIAN CANCER IMMUNOTHERAPY

$728,996FY2021Department of the ArmyDOD

The Univeristy Of Texas M.D. Anderson Cancer Center

Investigators